Redefining Pre-Heart Failure With Cardiac Biomarkers: Clinical and Research Implications
- PMID: 36892489
- DOI: 10.1016/j.jchf.2023.01.015
Redefining Pre-Heart Failure With Cardiac Biomarkers: Clinical and Research Implications
Keywords: biomarkers; heart failure; risk stratification.
Conflict of interest statement
Funding Support and Author Disclosures The National Institutes of Health (NIH) K23 Career Development Award 1K23HL143179 was awarded to Dr Shah. Dr Shah has received grant support to Inova from Abbott, Roche, Merck, and Bayer; and has done consulting for Procyrion, Natera, and Merck. Dr deFilippi has received research funding to Inova from Abbott Diagnostics, FujiRebio, Ortho Diagnostics, Quidel, Roche Diagnostics, and Siemens Healthineers; has done consulting for FujiRebio, Ortho Diagnostics, Quidel, Roche Diagnostics, and Siemens Healthineers; and also has received unrelated research funding from the NIH R01HL154768, R01HL151293, R21AG072095, and 1UL1TR003015. Dr Arias has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Reclassification of Pre-Heart Failure Stages Using Cardiac Biomarkers: The ARIC Study.JACC Heart Fail. 2023 Apr;11(4):440-450. doi: 10.1016/j.jchf.2022.12.005. Epub 2023 Feb 1. JACC Heart Fail. 2023. PMID: 36881398 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
